No Stock Yet
TALS Talaris Therapeutics
1.720+0.090+5.52%
Post Mkt Price
1.7200.0000.00%
NamePositionSalaryService DateEducationAgeGenderUpdated
Mr. Scott RequadtPresident, Chief Executive Officer, Secretary and Director748.06K----54male04/29/2022
Ms. Mary Kay FentonChief Financial Officer, Treasurer and Principal Accounting Officer------58female04/29/2022
Dr. Suzanne T. Ildstad, M.D.Chief Scientific Officer and Director561.73K----69female04/29/2022
Dr. Nancy Krieger, M.D.Chief Medical Officer591.31K----56female04/29/2022
Mr. Michael ZdanowskiChief Technology Officer------55male04/29/2022
Dr. Francois Nader,M.D.Chairman of the Board83.46K----65male04/29/2022
Mr. Geoff MackayDirector40.86K----55male04/29/2022
Mr. Mark D. McdadeIndependent Director27.67K----66male04/29/2022
Dr. Sapna Srivastava, PhDIndependent Director412.18K----51female04/29/2022
Dr. Karen L. Smith, M.D.,PhDIndependent Director--------female05/17/2022
Dr. Gaurav Shah, M.D.Independent Director37.60K----47male04/29/2022
Mr. Sandip AgarwalaIndependent Director27.67K----42male04/29/2022
Company Overview
More
Talaris Therapeutics, Inc. engages in cell therapy. It develops methods of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Its technologies are used to treat inherited metabolic enzyme disorders, red blood cell disorders to induce tolerance to organ transplants, and to treat autoimmune disorders such as type 1 diabetes, multiple sclerosis, rheumatoid arthritis, and scleroderma. The company was founded by Suzanne Ildstad on February 15, 2002 and is headquartered in Louisville, KY.
CEO： Mr. Scott Requadt
Market： NASDAQ
Listing Date： 05/07/2021
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist